Navigating Every Step of the Cancer Journey

At CURE, we strive to provide insight, education and inspiration for patients, survivors and caregivers at every stage of the cancer journey. That will be readily apparent as you flip through the pages of our latest seasonal issue, which covers everything from the initial complexities of a new diagnosis to the long-term, evolving emotional landscape of survivorship and caregiving. As we enter spring 2026, the pace of progress in oncology continues to accelerate, but we remain steadfast in our mission: to ensure that no one has to navigate this path without a reliable compass.

As part of CURE’s drive to educate our readership, in this issue, we provide a foundational guide for those navigating a stage 2 prostate cancer diagnosis. We understand that hearing the words “stage 2” brings a unique set of questions: How aggressive is this? What are my surgical vs radiation options? How will this affect my quality of life? This guide, part of our ongoing patient education efforts, is designed to demystify the staging process and explain how localized cancer is managed in the modern era. Although every patient’s biology is unique, we believe that providing this information serves as a vital starting point for empowered discussions between patients and their oncology teams. Knowledge is not just power — it is the antidote to the fear of the unknown.

We also take a deep dive into the social and emotional hurdles that often accompany a diagnosis, specifically addressing the persistent stigmas faced by patients with lung cancer. It is a harsh reality that many patients feel a sense of judgment or isolation due to the historical associations of the disease. In this issue, we confront these misconceptions head-on. We emphasize that lung cancer is a biological reality that can affect anyone with lungs, regardless of their history. By dismantling these stigmas, we aim to foster a more supportive, compassionate and understanding community where the focus remains where it belongs: on healing and support, not on blame.

In our latest installment of the "Speaking Out" series, we shift our focus to the rapidly evolving treatment landscape of multiple myeloma in a conversation with Dr. Joseph Mikhael, chief medical officer of the International Myeloma Foundation. This is an era of unprecedented innovation in hematologic oncology. From the refinement of chimeric antigen receptor T cell therapies to the emergence of bispecific antibodies, the options available to patients today were nearly unimaginable just a decade ago. These stories of scientific triumph offer a beacon of hope for patients looking toward a future defined by more than just their next treatment cycle.

Moving into the vital role of the support system, we address the reality that cancer is a "we" disease, not an "I" disease. Columnist Debbie Legault sheds light on the long-term emotional journey of the caregiver in a way that is both raw and deeply resonant. In her poignant piece, “Cancer and Answering the Phone,” she explores the specific brand of anxiety that persists long after the initial crisis has passed. For a caregiver, every ring of the phone can trigger a rush of adrenaline and fear. Legault’s work reminds us that the impact of cancer resonates far beyond the patient alone; it reshapes the psychological world of the spouse, the child and the friend. We are proud to provide a platform for these voices, ensuring that caregivers feel seen and supported in their own right.

CURE remains committed to being your most trusted source for both the science and the soul of cancer care. For all the latest updates in oncology, including breaking news on Food and Drug Administration approvals of new treatments and expert perspectives on key cancer information, you can always visit curetoday.com.

In the pages of this issue and on our website, you will find both personal stories that resonate and expert opinions to provide context. Whether you are a patient recently diagnosed, a long-term survivor or a caregiver holding the line, we hope this information serves you well and offers the encouragement and support you deserve.

Mike Hennessy Jr.

Chairman and CEO

MJH Life Sciences®